As previously noted, CRC, unlike other cancers, does not represent a clear case in which therapies based on PD-1 or PD-L1 inhibition have transformed treatment paradigms or significantly altered disease progression over the years. This evidence concerns the gene CD274 and colorectal carcinoma.